[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352209-105":59,"doc-detail-352209-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","factors-associated-with-omission-of-axillary-lymph-node-dissection-for-patients-with-clinical-node-positive-breast-cancer-who-have-residual-nodal-disease-on-pathology-after-neoadjuvant-chemotherapy-original-article-breast-oncology","Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy - Original Article - Breast Oncology","","Breast cancer patients with clinically node-positive (cN+) disease who retain residual nodal disease after neoadjuvant chemotherapy (NAC) represent a population in which axillary lymph node dissection (ALND) is traditionally standard. This retrospective observational study assessed, within the National Cancer Database from 2016 to 2021, factors linked to omitting ALND after sentinel lymph node biopsy (SLNB) in pathologically node-positive (ypN+) patients. Outcomes included axillary strategy patterns over time and associations by sociodemographic, geographic, and clinical variables using logistic regression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/factors-associated-with-omission-of-axillary-lymph-node-dissection-for-patients-with-clinical-node-positive-breast-cancer-who-have-residual-nodal-disease-on-pathology-after-neoadjuvant-chemotherapy-original-article-breast-oncology/352209/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/factors-associated-with-omission-of-axillary-lymph-node-dissection-for-patients-with-clinical-node-positive-breast-cancer-who-have-residual-nodal-disease-on-pathology-after-neoadjuvant-chemotherapy-original-article-breast-oncology/352209.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical scenario does this study focus on?","Question",{"text":112,"@type":113},"Patients with clinically node-positive breast cancer (cN+) who have residual nodal disease after neoadjuvant chemotherapy (NAC), specifically those who are pathologically node-positive (ypN+) after SLNB.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were axillary procedures categorized in the analysis?",{"text":117,"@type":113},"Axillary management was grouped as SLNB alone, SLNB followed by ALND (SLNB + ALND), or ALND alone.",{"name":119,"@type":110,"acceptedAnswer":120},"Which types of programs were associated with higher odds of SLNB alone versus SLNB + ALND?",{"text":121,"@type":113},"Compared with academic programs, comprehensive community, integrated network, and community programs had greater odds of SLNB alone relative to SLNB + ALND.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352209,1790142235,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[https://doi.org/10.1245/s10434-026-19968-5](https://doi.org/10.1245/s10434-026-19968-5)  \nAnnals of Surgical Oncology (2026) 33:9035–9048  \nORIGINAL ARTICLE BREAST ONCOLOGY  \nFactors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node‑Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy  \nNicole Rademacher, MD, MSPH1 · Lily A. Gutnik, MD, MSPH1 · Kristy K. Broman, MD, MSPH1,2,3  \nReceived: 25 March 2026 / Accepted: 28 May 2026 / Published online: 26 June 2026 © The Author(s) 2026  \nAbstract  \nBackground For breast cancer patients with clinically node-positive (cN+) and residual disease after neoadjuvant chemotherapy (NAC), axillary lymph node dissection (ALND) remains the standard of care, though alternative strategies may be selected by multidisciplinary teams in certain cases. This study evaluated factors associated with omission of ALND for cN+ patients who were pathologically node-positive after NAC (ypN+) .  \nMethods In this retrospective observational study, the National Cancer Database was queried for patients with clinical T1– T4, N1–N3 breast cancer from 2016 to 2021 who received NAC and were subsequently ypN+ . Axillary procedures were categorized as sentinel lymph node biopsy (SLNB) alone, SLNB followed by ALND (SLNB + ALND), or ALND alone. Logistic regression identified factors associated with omission of ALND after SLNB, adjusting for sociodemographic, geographic, and clinical variables.  \nResults Among 38,559 patients, axillary interventions were SLNB alone (n = 7,131, 18.49%), SLNB+ALND (n = 14,247, 36.95%), and ALND alone (n = 17,179, 44.55%) . Over the study period, SLNB alone and SLNB + ALND increased while ALND alone decreased. Compared with academic programs, patients treated at comprehensive community, integrated network, and community programs had greater odds of SLNB alone compared with SLNB+ALND (odds ratio [OR] 1.32, 95% confidence interval [CI] 1.22–1.43; OR 1.17, 95% CI 1.07–1.27; OR 1.54, 95% CI 1.33–1.78, respectively) .  \nConclusions There has been de-escalation of ALND after initial SLNB for cN+ breast cancer patients found to be ypN+ . This suggests that providers may be extrapolating evidence supporting SLNB alone to populations in which it has not yet been thoroughly studied or are omitting ALND in anticipation of ongoing clinical trial results.  \nKeywords Breast cancer · Axillary surgery · Node-positive breast cancer · Residual axillary disease · De-escalation  \nOver the past two decades, surgical management of breast cancer, and management of the axilla in particular, has evolved substantially, driven in part by growing evidence supporting de-escalation of axillary surgery. 1 Several studies, including ACOSOG Z0011, AMAROS, and  \n* Nicole Rademacher, MD, MSPH[nrademacher@uabmc.edu](nrademacher@uabmc.edu)  \n1 Department of Surgery, University of Alabama at Birmingham, Birmingham, AL  \n2 Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL  \n3 The University of Texas MD Anderson Cancer Center, Houston, TX  \nSENOMAC, in patients who did not receive neoadjuvant chemotherapy (NAC), as well as ACOSOG Z1071, SENTINA, GANEA2, and SN FNAC in patients with clinically node-positive disease who received NAC, have supported tailored approaches to axillary management in which axillary lymph node dissection (ALND) may be safely de-implemented in select patients.2–9  \nFor clinically node positive (cN+) patients who receive NAC, historical surgical standard of care has been ALND. However, recent studies have shown that in select patients with cN+ breast cancer who convert to clinically node negative (cN0) after NAC, sentinel lymph node biopsy (SLNB) or SLNB with removal of the marked/clipped node (targeted axillary dissection [TAD]) are appropriate and can be used  \nfor staging and definitive axillary surgery for those achieving ypN0 .10–14 Currently, for patients with cN+ dise","cbCaiqN6vgEGNGb4","https://ap.wps.com/l/cbCaiqN6vgEGNGb4","pdf",634263,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Axillary management and de-escalation evidence\n# Methods\n## Study design, setting, and participants","[{\"question\":\"What clinical scenario does this study focus on?\",\"answer\":\"Patients with clinically node-positive breast cancer (cN+) who have residual nodal disease after neoadjuvant chemotherapy (NAC), specifically those who are pathologically node-positive (ypN+) after SLNB.\"},{\"question\":\"How were axillary procedures categorized in the analysis?\",\"answer\":\"Axillary management was grouped as SLNB alone, SLNB followed by ALND (SLNB + ALND), or ALND alone.\"},{\"question\":\"Which types of programs were associated with higher odds of SLNB alone versus SLNB + ALND?\",\"answer\":\"Compared with academic programs, comprehensive community, integrated network, and community programs had greater odds of SLNB alone relative to SLNB + ALND.\"}]","Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy - Original Article - Breast Oncology | PDF",1790098303,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/626e785ab9affc6a7d90010d2eccc31e.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42fff46f2e510c4bbadfdd08396e67b1.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16eb8e2c26b95e6501f274df8dd1cffe.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c6de34115b49da2bdc75a21d2352bf4.webp",980,1301]